M
M. Milella
Researcher at University of Texas MD Anderson Cancer Center
Publications - 16
Citations - 1843
M. Milella is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: MAPK/ERK pathway & Kinase. The author has an hindex of 12, co-authored 16 publications receiving 1747 citations. Previous affiliations of M. Milella include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Linda S. Steelman,Steve L. Abrams,Jarrett T. Whelan,Fred E. Bertrand,D. E. Ludwig,Jörg Bäsecke,Massimo Libra,Franca Stivala,M. Milella,Agostino Tafuri,Paolo Lunghi,Antonio Bonati,Alberto M. Martelli,James A. McCubrey +13 more
TL;DR: The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT signaling cascades are described and recent data regarding the regulation and mutation status of these pathways and their involvement in leukemia are summarized.
Journal ArticleDOI
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia
M. Milella,Steven M. Kornblau,Zeev Estrov,Bing Z. Carter,Hélène Lapillonne,David Harris,Marina Konopleva,Shourong Zhao,Elihu Estey,Michael Andreeff +9 more
TL;DR: It is demonstrated that small-molecule MEK inhibitors profoundly impair cell growth and survival of acute myeloid leukemia (AML) cell lines and primary samples with constitutive MAPK activation and Interruption of constitutive MEK/MAPK signaling represents a promising therapeutic strategy in AML.
Journal ArticleDOI
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
James A. McCubrey,Linda S. Steelman,Steve L. Abrams,Fred E. Bertrand,D. E. Ludwig,Jörg Bäsecke,Massimo Libra,Franca Stivala,M. Milella,Agostino Tafuri,Paolo Lunghi,Antonio Bonati,Alberto M. Martelli,Alberto M. Martelli +13 more
TL;DR: It may be possible to combine various chemotherapeutic and antibody-based therapies with low molecular weight, cell membrane-permeable inhibitors which target the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to ultimately suppress the survival pathways, induce apoptosis and inhibit leukemic growth.
Journal ArticleDOI
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
Shourong Zhao,Marina Konopleva,Marina Konopleva,Maria Cabreira-Hansen,Maria Cabreira-Hansen,Zhong Xie,Zhong Xie,Wei Hu,M. Milella,M. Milella,Zeev Estrov,Gordon B. Mills,M. Andreeff,M. Andreeff +13 more
TL;DR: The data suggest that the inhibition of the PI3K/AKT signaling pathway restores apoptosis in AML and may be explored as a novel target for molecular therapeutics inAML.
Journal ArticleDOI
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Marina Konopleva,M. Milella,Peter P. Ruvolo,J C Watts,Maria Rosaria Ricciardi,Borys Korchin,Teresa McQueen,William G. Bornmann,Twee Tsao,Paola Bergamo,Duncan H. Mak,Weina Chen,James A. McCubrey,Agostino Tafuri,M. Andreeff +14 more
TL;DR: It is reported that, unexpectedly, ABT-737 induces activation of the extracellular receptor activated kinase and induction of MCL-1 in AML cells and concomitant inhibition by BH3 mimetics and MEK inhibitors could abrogate this effect and may be developed into a novel and effective therapeutic strategy for patients with AML.